Skip to main content

Table 4 Adjust of demographic factors for CKD

From: Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways

Variate CKD (3 to 5 stages) CKD (4 and 5 stages) CKD (3 stage)
HR (95% CI) p HR (95% CI) p HR (95% CI) p
KA 0.701 (0.276–1.783) 0.4556 0.115 (0.021–0.639) 0.0134 0.490 (0.086–2.806) 0.4230
Gender 1.155 (0.324–4.122) 0.8243 1.631 (0.174–15.291) 0.6684 0.807 (0.069–9.486) 0.8645
Age 0.958 (0.919–0.999) 0.0456 0.914 (0.856–0.976) 0.0069 0.988 (0.926–1.055) 0.7200
Complication 0.394 (0.109–1.421) 0.1547 0.272 (0.032–2.318) 0.2338 0.656 (0.110–3.903) 0.6429
Smoke 1.221 (0.534–2.794) 0.6363 4.069 (1.073–15.436) 0.0391 0.538 (0.175–1.654) 0.2793
Alcohol 1.192 (0.249–5.691) 0.8261 0.048 (0.001–1.744) 0.0976 11.172 (0.878–142.131) 0.0629
Education 0.473 (0.203–1.099) 0.0818 0.478 (0.108–2.120) 0.3313 0.288 (0.057–1.462) 0.1331
Occupation 1.363 (0.708–2.625) 0.3547 2.231 (0.847–5.876) 0.1043 1.264 (0.371–4.309) 0.7084
  1. Italic values indicate significance of p < 0.05